knowledge -WSS

knowledge

author：leisure time 2025-09-28 01:35:12 - browse：8582

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： John Green on his newest strategy for fighting tuberculosis

knowledge

hotspot

WSS

Boston's new lab space is opening empty

WuXi out of biotech trade group, U.S. and China relations to blame

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

UCLA team creates talking throat patch for voice disorders

UCLA team creates talking throat patch for voice disorders

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Steward Health Care Massachusetts hospitals face fiscal disaster

Apple is now the first public company to be valued at $3 trillion

First U.S. drug developed to treat liver disease MASH is approved

The cancer drug shortage isn’t new — and neither are the solutions

Ebola: Gilead Sciences antiviral shows promise as new treatment

Cancer drug shortages should be causing more outrage

Change Healthcare outage fallout shows need for new oversight

Walensky prepares to leave CDC — and Congress — behind

President Biden's budget: Here's what you might have missed

entertainment

President Biden's budget: Here's what you might have missed

As AI in medicine takes off, can 'human in the loop' prevent harm?

John Green on his newest strategy for fighting tuberculosis

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

RaDonda Vaught links Vanderbilt hospital issues to patient death

knowledge

hotspot

hotspot

explore